A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

While intensity didn’t appear to matter in this network meta-analysis, location did: in-person programs had the most impact.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

Following the recent IDE Approval by the U.S. Food and Drug Administration (FDA) for MagicTouch PTA, this enrolment heralds ...

A study comparing men and women suggests much of the association arises from genetic propensity to both conditions.

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

In a field rife with disagreement, STS, AATS, and others say the European guidelines got it right when it comes to CABG.

Fitness doesn’t make people immune to atherosclerosis, but what to do with the finding in asymptomatic patients is uncertain.

Greater transparency, monitoring, and regulatory oversight are needed around these transactions, a researcher says.

The ARIES-HM3 substudy may help persuade implanters who are less well-versed in the circulatory changes an LVAD affords.